ProfileGDS5678 / 1444530_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 44% 39% 39% 39% 44% 37% 37% 39% 39% 39% 38% 39% 40% 39% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 13.0642744
GSM967853U87-EV human glioblastoma xenograft - Control 22.8907939
GSM967854U87-EV human glioblastoma xenograft - Control 32.8923239
GSM967855U87-EV human glioblastoma xenograft - Control 42.83239
GSM967856U87-EV human glioblastoma xenograft - Control 52.9602844
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 12.9165837
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 22.9100937
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 32.8715839
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 42.8681339
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 12.8848439
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 22.8705138
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 32.8701239
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 42.923440
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 52.8810939